Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could

The article argues that ADMA Biologics, EyePoint Pharmaceuticals, and Viking Therapeutics all have realistic paths to doubling, driven by profitable growth, late-stage clinical catalysts, and large addressable markets. ADMA is already profitable with Q1 net income of $407 million and consensus upside near 100%-140%, while EyePoint and Viking each have consensus upside of 165% and 146%, respectively. The piece is largely a bullish stock-picking commentary rather than a fresh company-specific catalyst, so near-term market impact should be limited.

Analysis

The market is starting to reward late-stage biotech with visible catalyst sequencing and a credible path to self-funding, while punishing capital-intensive “story” names without near-term monetization. ADMA is the cleanest expression of that shift: if management keeps compounding yields and plasma utilization, the rerating can come from both earnings growth and multiple expansion, which is a more durable setup than a pure pipeline bet. The second-order implication is bearish for smaller plasma peers that lack manufacturing leverage, because investors will increasingly benchmark them against ADMA’s profitability profile rather than against each other.

EyePoint and Viking are both binary catalyst names, but their upside is likely to be realized through different channels. EyePoint’s data readouts can de-risk commercial durability faster because ophthalmology is a physician-switching market with high repeat utilization, whereas Viking’s path depends more on obesity differentiation versus entrenched incumbents and payer scrutiny. If VK2735 shows tolerability or titration advantages, the optionality is not just share gain; it could force pricing discipline across the GLP-1 ecosystem and pressure smaller oral-obesity aspirants before they ever reach scale.

The consensus appears to be underpricing time-to-value for ADMA and overpricing certainty for the higher-beta development names. The biggest near-term risk is not clinical failure alone, but a “good but not good enough” outcome that triggers multiple compression after a fast run-up. Over the next 1-3 months, catalyst timing matters more than fundamentals; over 6-18 months, reimbursement, scale-up, and manufacturing execution will decide whether these stocks become doubling stories or merely high-volatility trading vehicles.

Key Decisions for Investors

• Long ADMA on any broad biotech weakness; target a 6-12 month hold with asymmetric upside if execution stays on track. Use a staggered entry because the rerating can continue even after a positive quarter as analysts model higher yield-driven margins.
• Buy EYPT ahead of data, but size as a catalyst trade rather than a core position. Best risk/reward is through call spreads or a small equity long into the readout window, with strict trim discipline if the data are merely incremental.
• Long VKTX vs. short a basket of lower-quality obesity names or stretched GLP-1 proxies; this isolates upside from differentiated data while reducing market beta. The trade works best into late-stage updates over the next 2-4 quarters.
• If already long VKTX, hedge with downside puts into binary clinical milestones. The market will likely punish any tolerability ambiguity harder than efficacy disappointment because obesity winners must scale commercially, not just biologically.
• Avoid chasing the most extended names after catalyst headlines; instead, rotate into post-event pullbacks where analyst targets remain far above spot but execution risk is no longer theoretical.